GDC-0084

Phase 1Small molecule

Roche

GDC-0084 is one of 11 small molecule programs targeting Leptomeningeal Metastases. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Leptomeningeal MetastasesActive, not recruiting

Leptomeningeal MetastasesPhase 1

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Leptomeningeal Metastases

#DrugCompanyPhaseTrials

Lorbrena

Pfizer

Approved

1 2

Firmonertinib

AAllist Pharmaceuticals, Inc.

Phase 3

1 3

Alimta

SShawn Eagle

Phase 2

3 4

Desferal

Jazz Pharmaceuticals

Phase 1

1 5

Avastin

Roche

Phase 1

1 6

Furmonertinib

AAllist Pharmaceuticals, Inc.

Phase 2

1 7

Intrathecal Chemotherapy

PPrincess Maxima Center for Pediatric Oncology

Phase 2

1 8

Intrathecal Pemetrexed

HHunan Province Tumor Hospital

Phase 2

1 9

Ivonescimab Combined With Chemotherapy

SSun Yat-sen University

Preclinical

1 10

186rnl

NNYU Langone Health

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Leptomeningeal Metastases

NCT04192981

Clinical

Trials by Indication[1]

Glioma1 trial

A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma

Completed· Roche logo

Roche·Phase 1·NCT01547546·29 enrolled

Breast Cancer1 trial

GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases

Terminated·—·Phase 2·NCT03765983·17 enrolled

Diffuse Intrinsic Pontine Glioma1 trial

Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT03696355·27 enrolled

Leptomeningeal Metastases1 trial

GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04192981·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for GDC-0084. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GDC-0084 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GDC-0084. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Roche

GDC-0084

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Glioma1 trial

Breast Cancer1 trial

Diffuse Intrinsic Pontine Glioma1 trial

Leptomeningeal Metastases1 trial

References

Drug Info

Quick Facts

Related News